PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Bid/Ask 14:02:51 2024-07-02 EDT | After market 15:05:02 | |||
| 1.04 EUR | +26.83% |
|
1.105 | +6.25% |
| Current month | +14.29% | ||
| 1 month | -48.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 1.04 | +26.83% |
| 24-07-01 | 0.82 | -9.89% |
| 24-06-28 | 0.91 | +2.25% |
| 24-06-27 | 0.89 | -2.20% |
| 24-06-26 | 0.91 | +33.82% |
Real-time Boerse Frankfurt Warrants
Last update July 02, 2024 at 02:02 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1JLR |
| ISIN | DE000VD1JLR9 |
| Date issued | 2024-03-05 |
| Strike | 1,069 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.8 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.17 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.07 € |
| Spread % | 6.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,005
DKK
Average target price
952.2
DKK
Spread / Average Target
-5.22%
- Stock Market
- Certificates
- Certificat
